White Paper

Gene Therapies In Hemophilia

By David Carr & Larry Blandford

Cell and Gene genetic lab iStock-1209892070

Potentially curative gene therapies for hemophilia are getting closer to market, representing a transformation in care for many thousands of patients. But all is not so simple, and the fact that these gene therapies could positively impact so many people presents a new challenge for the growing impact of advanced therapies. So far, gene therapies have targeted smaller, rare, or ultra-rare indications with a high disease burden, which means access stakeholders have been more forgiving on the evidence requirements, and the high treatment costs haven’t had major impacts on budgets. Download the available white paper to find out more.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene